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Introduction
Microdialysis is unique in that it allows the chemistry of
the extracellular interstitial fluid to be monitored con-
tinuously. Since its conception by Ungerstedt and
Pycock in the 1970s [1] and its introduction into clinical
practice approximately 25 years ago [2], it has been
applied to study the tissue chemistry of several human
organs. Most experience has been acquired in the setting
of neurocritical care. In this arena, microdialysis has
been applied to patients with several conditions, and in
particular traumatic brain injury (TBI) and subarachnoid
hemorrhage (SAH). There is no doubt that this tech-
nique has increased our understanding of the
pathophysiology of these disease processes [3]. Fur-
thermore, microdialysis has evolved into a clinical tool
for the management of patients on an individual inten-
tion-to-treat basis.
In neurocritical care, microdialysis data is typically
collected together with intracranial pressure (ICP) [al-
lowing calculation of cerebral perfusion pressure (CPP)]
and brain tissue oxygen tension (PbtO2). Microdialysis
complements these techniques by providing additional
information on substrate delivery and metabolism at the
cellular level. It thus provides the most direct means to
monitor the fundamental process of ‘‘energy failure’’. Of
critical importance is that such measurements can be
made in real time at the bedside.
In 2003, a group of experts met to review the status of
microdialysis as a clinical monitor. This culminated in the
publication of a consensus statement in 2004 [4] provid-
ing guidance on the use of the technique in TBI and SAH
patients. More recently, the role of microdialysis has
been evaluated by participants of the International Mul-
tidisciplinary Consensus Conference on Multimodality
Monitoring [5].
In April 2014, an international forum was convened in
Cambridge, UK, with the aim of reviewing evidence for
the clinical application of microdialysis in neurocritical
care and producing a revised and updated consensus
statement [4]. Since the original consensus statement,
*680 articles have been published on microdialysis in
neurocritical care. With this increased experience, there
was a need to update the 2004 consensus statement.
Although there was some overlap between the objectives
of this meeting and that of the International Multidisci-
plinary Consensus Conference on Multimodality
Monitoring, i.e. to review the evidence for using micro-
dialysis to guide clinical care, the principal objective of
the International Forum in Microdialysis differed in that
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Abstract Microdialysis enables the
chemistry of the extracellular inter-
stitial space to be monitored. Use of
this technique in patients with acute
brain injury has increased our under-
standing of the pathophysiology of
several acute neurological disorders.
In 2004, a consensus document on the
clinical application of cerebral
microdialysis was published. Since
then, there have been significant
advances in the clinical use of
microdialysis in neurocritical care.
The objective of this review is to
report on the International Micro-
dialysis Forum held in Cambridge,
UK, in April 2014 and to produce a
revised and updated consensus state-
ment about its clinical use including
technique, data interpretation, rela-
tionship with outcome, role in
guiding therapy in neurocritical care
and research applications.
Keywords Brain chemistry 
Microdialysis  Outcome 
Subarachnoid hemorrhage 
Traumatic brain injury
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we aimed to combine literature review with expert opin-
ion to produce practical guidance for the use of cerebral
microdialysis as a clinical monitor and to help guide
future clinical studies utilizing cerebral microdialysis.
Methods
The senior authors selected specific ‘key speakers’ to
review a particular area of the literature. These individ-
uals were selected based on their experience and
contribution to the literature on a particular aspect of
microdialysis monitoring. See Appendix 1 in the supple-
mentary material for a list of key speakers and for the
topics they each reviewed. The other participants of the
meeting were identified through literature review and by
correspondence with the key speakers who were able to
identify other clinicians and scientists active in using
microdialysis in neurocritical care patients. At the meet-
ing, the literature was presented to the whole group
followed by discussion to allow consensus generation.
After the meeting, the recommendations were circulated
to all participants allowing further discussion and
revision.
In addition, for the purposes of the consensus state-
ment, we performed a PubMed database search using the
term microdialysis plus one of the following terms:
‘traumatic brain injury’, ‘brain injury’, ‘trauma’, ‘sub-
arachnoid hemorrhage’, ‘stroke’, ‘epilepsy’, ‘intracerebral
hematoma’ and ‘cost effectiveness’. We restricted our
review to using articles published in the English language.
Where recommendations are based on published obser-
vational data, the relevant references are given although
formal grading was not performed. Where references are
not provided, the recommendations are based on expert
opinion.
Discussion
Advances since the 2004 consensus statement
Over the past 10 years, there have been significant
advances in the clinical utility of microdialysis in neur-
ocritical care. Evidence from large numbers of patients on
how brain chemistry relates to clinical outcome means
that we can better define pathological thresholds for
microdialysis values. In addition, there is increasing evi-
dence of how different therapeutic manoeuvres can
improve chemistry. For a summary of the main advances
since the 2004 consensus statement, please see Table 1.
Most attention has been directed at the clinical utility
to monitor TBI and SAH patients: see Table 2 for a
summary of how brain chemistry relates to different
aspects of the care of patients with TBI and SAH.
Microdialysis has also been used in other neurological
conditions including intracerebral hemorrhage [6], acute
ischemic stroke [7–9], hepatic encephalopathy [10] and
epilepsy [11, 12]. However, there is insufficient evidence
at present to specifically incorporate the application of
Table 1 Summary of advances since the consensus statement by [4]
2004 consensus statement [4] Current consensus statement
Microdialysis methodology Monitoring of small molecules using
standard 10-mm 20-kDa catheter
Advances in monitoring of large molecules, with experience of
using 100-kDa membrane and colloid for perfusate [13–20]
Focus on microdialysis metabolites
as a marker of ischemia and cell
damage
Novel applications of microdialysis for monitoring and
understanding brain pathology following TBI and SAH
Core data reporting information Not defined Details are given of the essential information required to
interpret and compare microdialysis data
Reference values Not defined Pathological thresholds defined for glucose, lactate and the LP
ratio [6, 51, 53–55, 68–73, 79, 80]
Tiered approach to
microdialysis metabolites for
clinical application
Not defined Glucose and LP ratio more clinically useful than glutamate and
glycerol in TBI and SAH patients
Guidance for microdialysis-
directed management
Not given Suggested therapeutic interventions for when glucose is low
(\0.2 mM) and for when the LP ratio indicates
ischemia ± tissue hypoxia
Monitoring in TBI Guidance on catheter placement in
focal or diffuse injury
Guidance on single or multiple catheter placement based on
whether the injury is focal or diffuse and based on the aims of
microdialysis monitoring
Monitoring in SAH Guidance on catheter placement in
the tissue at risk
Two principal indications for microdialysis monitoring are
defined:
1. As a primary monitoring device in mechanically ventilated
patients
2. As a monitor of patients with a secondary neurological
deterioration
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microdialysis in these conditions into the consensus
statement.
In addition to recent advances as a clinical monitor,
microdialysis continues to be a powerful research tool
with numerous, varied and several novel applications that
provide insight into various aspects of cerebral biology
and pathophysiology. For a summary of on-going and
future research, see Table 3. Overall, further research
should be directed at the integration of brain chemistry
and other clinical monitoring data to better define targets
for the individualized goal-directed management of the
brain-injured patient.
Advances in microdialysis methodology
The technique of microdialysis is well established. For
details on technique and on the factors that affect relative
recovery, i.e. how the substance measured in the dialysate
is related to the free concentration in the tissue interstitial
space, please see supplementary material.
Microdialysis is used clinically to estimate extracel-
lular interstitial concentrations of small molecules, but
can also be used to recover much larger molecules such as
inflammatory mediators from the interstitial fluid. Instead
of the standard 20-kDa nominal molecular weight cut-off
membrane, which recovers glucose, pyruvate, lactate,
glycerol, glutamate, and other small hydrophilic mole-
cules, a 100-kDa membrane is used to also recover larger
molecules including cytokines. The recovery of small
molecules does not differ between the two membrane
types [13]. Increased experience in using microdialysis
for large molecules less than 100 kDa has been achieved
in the past 10 years. Importantly, the use of colloid in the
perfusate (e.g., albumin or dextran) significantly improves
the relative recovery of these large molecules [14–16].
However, in some situations, colloid perfusate can cause
net influx of fluid into the catheter potentially dehydrating
the interstitial space, and dextrans of molecular weight
40–250 kDa may leak through the microdialysis
membrane potentially disturbing the interstitial microen-
vironment [14, 15, 17]. These problems may be overcome
by using higher molecular weight dextrans, such as
500-kDa dextran, as colloid in the perfusate [18–20]. A
useful alternative colloid to dextran is human serum
albumin (HAS), which has been shown to improve
recovery for the majority of cytokines compared to
crystalloid perfusate without significantly dehydrating the
interstitial space [16].
Most experience of microdialysis in neurocritical care
has been obtained with hourly measurements although
more frequent sampling is possible [21–25]. Hourly
sampling appears sufficient to detect the metabolic
changes that can sometimes precede episodes of
intracranial hypertension in TBI and symptomatic delayed
ischemia in SAH [26–29]. Hence, microdialysis has the
potential to be used as an early warning system of sec-
ondary insults. However, dynamic changes in brain
Table 2 Summary of the evidence for how brain chemistry relates to different aspects of the management of patients with TBI and SAH
How microdialysis monitoring can be used in neurocritical care Traumatic
brain injury
Subarachnoid
hemorrhage
Outcome and prognostication [51, 53, 78] [67, 79, 81]
Early warning system of secondary insults [26, 27] [28, 29, 80, 82]
Monitoring and treatment of low cerebral glucose; guiding systemic
glucose management and insulin use
[56, 61, 62, 64, 65] [56, 63, 83, 84]
Monitoring during CPP-augmentation/reduction [48, 85, 86] [54, 87]
Monitoring during neurological wake-up test (tolerating moderate rises in ICP) [25, 88]
Deciding on transfusion thresholds [89]
Evaluating the effect of body temperature on cerebral chemistry [90] [91]
Monitoring after decompressive craniectomy [92] [93]
Table 3 A summary of on-going microdialysis research applications
Investigating the concept of lactate as a substrate as opposed to a metabolic by-product in select patients [79, 94]
Use of 100-kDa microdialysis membranes to measure larger molecules including cytokines [15, 16, 18, 19, 95]
Use of 13C-labelled substrates to interrogate metabolic pathways in more detail, e.g., the fate of glucose
metabolism (glycolysis vs. pentose phosphate pathway) and the fate of lactate as a substrate
[94, 96, 97]
Monitoring drug penetration across the blood–brain barrier and the effect of drugs on brain chemistry [98, 99]
Clinical use in pediatric practice [100–102]
Monitoring of the ionic component of the interstitial space [103]
Monitoring of biomarkers [18, 19, 104–111]
Development of microfluidic based on-line assays that give continuous neurochemical information in real time [23, 24, 112]
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chemistry, for example due to spreading depolarization
[21–23] or observed during aneurysm surgery [24, 30],
may not be detected with hourly measurements, so there
is potentially scope for improved technology with more
frequent microdialysis readings in future, which may lead
to better warning of adverse events.
Clinical application in intensive care
The clinical application of microdialysis in neurocritical
care has focused on the delivery of glucose and its
metabolism via glycolysis to pyruvate, which under
oxidative conditions feeds into the tricarboxylic acid
(TCA) cycle. Under hypoxic conditions, or if mitochon-
drial function is compromised, pyruvate is metabolized to
lactate. Hence, the LP ratio is used as a marker of aerobic
versus ‘‘anaerobic’’ metabolism not requiring oxygen [31,
32]. Glutamate is measured as a marker of hypoxia/is-
chemia and has been considered as an indicator of
excitotoxicity [31–34]. Glycerol is regarded a marker of
hypoxia/ischemia and cell membrane breakdown [32, 35–
37].
Safety profile
The technique of cerebral microdialysis is safe. Several
published series of patients studied with microdialysis,
which include non-brain-injured patients, have not
reported adverse events related to microdialysis catheter
insertion [29, 38–40]. Cerebral microdialysis has a safety
profile at least equivalent to that of intra-parenchymal
pressure sensors owing to the catheter’s greater flexibility
and small diameter [41]. In most circumstances when an
adverse event occurs, it relates to the insertion technique
rather than the catheter itself. Cerebral microdialysis has
mostly been used as a tool for observational studies.
Further evaluation of microdialysis as a clinical monitor
should include assessment of potential harm caused by
microdialysis-directed interventions.
Cost-benefit analysis
No cost effectiveness studies evaluating microdialysis in
neurocritical care have been performed. One study com-
pared ICP monitoring alone against multimodal
monitoring, which consisted of transcranial Doppler,
jugular venous oxygen saturation and/or PbtO2 monitor-
ing but not microdialysis [42]. Albeit a small study, it
demonstrated that increased upfront costs due to con-
sumables and equipment was offset by better clinical
outcomes, which meant that multimodal monitoring was
cost effective. In TBI patients, there are indications that
aggressive management, which includes invasive
monitoring, improves outcomes and is cost effective [43–
46]. However, these studies have not examined micro-
dialysis monitoring per se.
Recommendations from the 2014 International
Forum on Microdialysis––the 2014 consensus
statement
Methodology
• Catheters should be inserted according to local insti-
tutional protocols either by twist drill hole, transcranial
bolt, or at craniotomy.
• The first hour of microdialysate collected should not be
used for clinical monitoring due to unreliable results
caused by insertion trauma and the pump flush
sequence.
• To monitor glucose, pyruvate, lactate, glycerol and
glutamate catheters with a 20- or 100-kDa cut-off are
available (100-kDa catheters are not yet FDA-approved,
although they are CE marked for use in Europe).
• A flow rate of 0.3 lL/min with hourly sampling is
recommended, which is the flow rate most commonly
used in the cerebral microdialysis literature.
• Publication of microdialysis data should include the
following information (core data reporting):
• catheter type
• catheter location based on post-insertion imaging
• flow rate
• membrane length
• perfusion fluid composition
• time from ictus to monitoring
Interpretation of cerebral microdialysis
• Microdialysis monitors substrate delivery and metabo-
lism at the cellular level. Chemistry should be
interpreted in the context of the clinical condition of the
patient and in conjunction with other monitored
parameters including ICP, CPP, PbtO2, cerebrovascular
pressure reactivity (PRx) and systemic parameters, in
order to determine the likely cause of perturbed meta-
bolism. For example, a rise in LP ratio associated with
a fall in CPP and loss of cerebrovascular reactivity (i.e.,
a high PRx) indicates that the likely cause of disordered
chemistry is ischemia.
• Microdialysis is a focal technique. The heterogeneity of
brain injury means that brain chemistry varies in
different regions of the brain. In TBI, peri-lesional
brain demonstrates more perturbed chemistry, in par-
ticular a higher LP ratio, compared to other areas of
brain [47–52]. Therefore, brain chemistry should be
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interpreted according to catheter location in relation to
focal injury based on CT/MRI imaging.
Glucose
• Glucose is the main substrate for brain metabolism.
• Periods of low glucose (\0.8 mM) are observed in TBI
and SAH.
• Low brain glucose is associated with unfavorable
outcome [53–57].
• There is also evidence that high brain glucose is
associated with unfavorable outcome indicating that
there is an optimal range for brain glucose, although,
there is currently insufficient data to define this range
[51, 58].
• Serum glucose concentration and glycemic control
influence brain glucose although this relationship may
be lost in injured brain [56, 59–65].
• Brain glucose can be reduced rapidly by secondary
insults such as spreading depolarization [22, 66].
Lactate/pyruvate ratio
• A high LP ratio is associated with unfavorable outcome
[6, 51, 53, 54, 57, 67–73].
• The LP ratio is a marker of cellular redox status.
• The LP ratio is a quantitative measure (independent of
relative recovery).
• An increased LP ratio may result from a failure of
oxygen delivery (ischemic hypoxia) or from non-
ischemic causes (e.g., mitochondrial dysfunction) [74,
75].
• The absolute lactate and pyruvate concentrations
should be considered when interpreting a high LP
ratio.
• Ischemia and mitochondrial dysfunction are two ends
of a spectrum of factors that increase the LP ratio.
• An increase in the LP ratio in the presence of low
pyruvate (and low oxygen) indicates ischemia.
• An increase in LP ratio in the presence of normal or
high pyruvate (and normal oxygen) indicates mito-
chondrial dysfunction.
Glutamate
• Glutamate is an excitatory amino acid and neurotrans-
mitter. Excess levels are thought to be an additional
injurious mechanism and may exacerbate injury in TBI
and SAH.
• Excess glutamate release is observed in ischemia [8,
31, 33, 76] and seizures [11, 12, 76, 77].
• There is a described association between glutamate
levels, clinical course and outcome in TBI and SAH
[29, 78].
• Measuring cerebral glutamate is an option and may be
useful in estimating prognosis.
Glycerol
• Glycerol is a marker of cell membrane breakdown. It is
a potential marker of oxidative stress.
• Glycerol has limited specificity; brain glycerol concen-
trations are influenced by systemic concentrations.
Systemic glycerol concentrations reflect a stress
response and/or administration of glycerol-containing
substances.
• There is no definitive evidence of a relationship
between glycerol and outcome.
• Cerebral glycerol is an option as a marker of cerebral
injury.
Guidance for use of microdialysis in traumatic brain
injury and subarachnoid hemorrhage—catheter
location, reference values and interventions
Traumatic brain injury
• In diffuse TBI, we recommend placing the catheter in
the right (non-dominant) frontal lobe.
• In focal TBI, there are different options for catheter
placement that depend on whether the goal is to
monitor tissue at risk or normal brain, e.g., to guide
systemic glucose treatment.
• Where there is a focal lesion, we recommend, if
feasible, catheter placement ipsilateral to the lesion and
in radiographically normal brain.
• Multiple catheters are an option in focal TBI.
• E.g., placed at craniotomy for a focal lesion into peri-
lesional brain with a contralateral ‘bolt’ catheter in
radiographically normal brain.
• Stereotactic placement is an option but rarely
practical.
Subarachnoid hemorrhage
• There are two principal indications for the insertion of
microdialysis in SAH patients:
1. As a primary monitoring device in mechanically
ventilated (‘poor-grade’) patients.
2. As a monitor of patients with a secondary neuro-
logical deterioration.
• As a primary monitoring device, we recommend
catheter location in the watershed anterior cerebral
artery–middle cerebral artery (ACA–MCA) territory
(frontal lobe) on the same side as the maximal blood
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load seen on CT or the ruptured aneurysm. If the blood
load is symmetrical, we recommend non-dominant
frontal lobe placement.
• In patients with a secondary neurological deterioration,
catheter location should be guided by local practice to
identify tissue at risk (e.g., CT perfusion scanning or
trans-cranial Doppler).
• Multiple catheters are an option in SAH.
Reference values and interventions
• It is currently difficult to define absolute normal or
abnormal values based on the literature. Different
groups have used different threshold values to relate
microdialysate values to outcome. Furthermore, some
authors have used a combination of values to relate
microdialysis to clinical outcomes.
• The trend is as important or possibly more important
than point values or threshold values.
• It is important to distinguish between normal values,
which have been reported in the awake and anes-
thetised brain of patients undergoing surgery for benign
intracranial lesions, and values that characterize patho-
physiological disturbance of brain chemistry.
• We propose the following pathological thresholds (one
or two stages), for microdialysis at 0.3 ll/min, based on
observational studies that have explored statistical
differences in outcomes in relation to thresholds of
microdialysate values. Microdialysate values observed
beyond these thresholds indicate that the area of brain
being monitored is ‘at risk’. We propose clinical
interventions that may be appropriate in response to
disturbed brain chemistry. Further research is needed to
elucidate whether these thresholds can be applied to
both peri-lesional and to radiographically normal brain
and to identify whether interventions directed by these
thresholds improve clinical outcomes.
• Glucose:\0.2 and\0.8 mmol/L [53–55, 73].
• If brain glucose is low (\0.2 mM), a trial of increasing
serum glucose (by intravenous or enteral administra-
tion and/or loosening glycemic control) should be
considered. Factors to consider when deciding whether
this is an appropriate intervention include baseline
serum glucose concentration and whether other
parameters indicate cerebral ischemia. If baseline
serum glucose concentration is high, further increasing
the glucose concentration is likely to increase the risk
of both neurological and systemic complications from
hyperglycemia. The precise definition of blood sugar
thresholds for safety is beyond the scope of this
manuscript, but frank hyperglycemia should be
avoided. If other parameters, such as the LP ratio
and PbtO2, indicate ischemia, interventions directed at
improving cerebral perfusion should be considered
first-line.
• Lactate:[4 mmol/L [51, 73, 79, 80].
• Lactate/pyruvate ratio:[25 and[40 [6, 51, 53, 54,
68–73].
• If the LP ratio indicates ischemia, i.e. an increase in
the LP ratio in the presence of low pyruvate, CPP
augmentation is a therapeutic option.
• If the LP ratio is increased in the presence of low brain
tissue oxygen, interventions that improve oxygen
delivery, such as judiciously increasing the cerebral
perfusion pressure, increasing PaCO2, increasing
inspired concentration of oxygen and/or correcting
anemia, should be considered. However, all of these
interventions have potential side effects, and the
choice of intervention will depend on the pre-
intervention levels of any given variable, and a
consideration of the side effects of the intervention.
Thus, for example, in patients with significant
hypocarbia, an increase in PaCO2 might be the most
appropriate intervention, but may be difficult to
achieve due to increases in intracranial pressure.
Tiered approach to the clinical value of substances
• Accumulating evidence since the last consensus state-
ment indicates that the value of the metabolites can
now be considered in a tiered fashion (tier 1 being most
robust and useful) for their clinical application as fol-
lows. This hierarchy is based on the larger volume of
observational data linking glucose and LP ratio with
outcome compared to glutamate and glycerol and on
the greater potential for glucose and LP ratio to direct
clinical interventions.
• Tier 1: glucose and LP ratio.
• Tier 2: glutamate.
• Tier 3: glycerol.
Summary and future directions
Cerebral microdialysis is a reliable and safe technique that
is used in the clinical management of neurocritical care
patients and in particular those with severe TBI or SAH. In
addition, there are several research applications that are
important for developing our understanding of brain phys-
iology, pathophysiology and drug development. Since the
2004 consensus document, there have been significant
advances in our understanding of how microdialysis can be
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used. There is now evidence from large numbers of patients
on how abnormal brain chemistry relates to clinical out-
come. The measurement of glucose, lactate and the LP ratio
are now considered more useful than glutamate and glyc-
erol. The LP ratio, interpreted in the light of absolute
pyruvate concentrations and PbtO2, can be used to differ-
entiate ischemic from non-ischemic causes of energy
dysfunction. Importantly, there is increasing evidence of
how different therapeutic manoeuvres influence brain
chemistry. Microdialysis is well placed to help guide the
management of patients in an individualized and targeted
fashion. For its effective use, microdialysis should be
integrated into brain multi-modal monitoring systems and
interpreted with knowledge of catheter location and clinical
context. Future clinical research should focus on assessing
the clinical effectiveness of decision-making based on
microdialysis, as part of multi-modality monitoring of acute
brain injured patients, and its integration into treatment
paradigms in neurocritical care.
Acknowledgments We gratefully acknowledge financial support
for participants as follows: P.J.H.—National Institute for Health
Research (NIHR) Professorship and the NIHR Biomedical Research
Centre, Cambridge; I.J.—Medical Research Council (G1002277 ID
98489); A. H.—Medical Research Council, Royal College of Sur-
geons of England; K.L.H.C.—NIHR Biomedical Research Centre,
Cambridge (Neuroscience Theme; Brain Injury and Repair Theme);
M.G.B.—Wellcome Trust Dept Health Healthcare Innovation
Challenge Fund (HICF-0510-080); L. H.—The Swedish Research
Council, VINNOVA and Uppsala Berzelii Technology Centre for
Neurodiagnostics; S. M.—Fondazione IRCCS Ca` Granda Ospedale
Maggiore Policlinico; D.K.M.—NIHR Senior Investigator Award to
D.K.M., NIHR Cambridge Biomedical Research Centre (Neuro-
science Theme), FP7 Program of the European Union; M. O.—
Swiss National Science Foundation and the Novartis Foundation for
Biomedical Research; J.S.—Fondo de Investigacio´n Sanitaria (In-
stituto de Salud Carlos III) (PI11/00700) co-financed by the
European Regional Development; M.S.—NIHR University College
London Hospitals Biomedical Research Centre; N. S.—Fondazione
IRCCS Ca` Granda Ospedale Maggiore Policlinico.
Conflicts of interest M Dialysis, Stockholm, Sweden, provided
financial support for the 2014 International Microdialysis Forum
although neither honorariums nor speaker fees were received by any
of the authors. M Dialysis were neither involved in designing the
structure of the meeting nor in selecting the participants. H.M.
received a travel grant from M Dialysis to attend the meeting. The
other authors have no conflicts of interest in relation to this manu-
script. An extended conflict of interest statement for all participants
is provided in the supplementary material (see Appendix 2).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits use,
duplication, adaptation, distribution, and reproduction in any
medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
1. Ungerstedt U, Pycock C (1974)
Functional correlates of dopamine
neurotransmission. Bull Schweiz Akad
Med Wiss 30:44–55
2. Persson L, Hillered L (1992) Chemical
monitoring of neurosurgical intensive
care patients using intracerebral
microdialysis. J Neurosurg 76:72–80.
doi:10.3171/jns.1992.76.1.0072
3. Hillered L, Vespa PM, Hovda DA
(2005) Translational neurochemical
research in acute human brain injury:
the current status and potential future
for cerebral microdialysis.
J Neurotrauma 22:3–41. doi:
10.1089/neu.2005.22.3
4. Bellander B-M, Cantais E, Enblad P
et al (2004) Consensus meeting on
microdialysis in neurointensive care.
Intensive Care Med 30:2166–2169.
doi:10.1007/s00134-004-2461-8
5. Hutchinson P, O’Phelan K, The
Participants in the International
Multidisciplinary Consensus
Conference on Multimodality
Monitoring (2014) International
multidisciplinary consensus
conference on multimodality
monitoring: cerebral metabolism.
Neurocrit Care 21:1–11. doi:
10.1007/s12028-014-0035-3
6. Nikaina I, Paterakis K, Paraforos G
et al (2012) Cerebral perfusion
pressure, microdialysis biochemistry,
and clinical outcome in patients with
spontaneous intracerebral hematomas.
J Crit Care 27:83–88. doi:
10.1016/j.jcrc.2011.04.004
7. Berger C, Scha¨bitz W-R, Georgiadis D
et al (2002) Effects of hypothermia on
excitatory amino acids and
metabolism in stroke patients: a
microdialysis study. Stroke
33:519–524. doi:
10.1161/hs0102.100878
8. Dohmen C, Bosche B, Graf R et al
(2003) Prediction of malignant course
in MCA infarction by PET and
microdialysis. Stroke 34:2152–2158.
doi:10.1161/01.STR.0000083624.
74929.32
9. Schneweis S, Grond M, Staub F et al
(2001) Predictive value of
neurochemical monitoring in large
middle cerebral artery infarction.
Stroke 32:1863–1867. doi:
10.1161/01.str.32.8.1863
10. Tofteng F, Jorgensen L, Hansen BA
et al (2002) Cerebral microdialysis in
patients with fulminant hepatic failure.
Hepatology 36:1333–1340. doi:
10.1002/hep.1840360607
11. During MJ, Spencer DD (1993)
Extracellular hippocampal glutamate
and spontaneous seizure in the
conscious human brain. Lancet
341:1607–1610. doi:
10.1016/0140-6736(93)90754-5
1524
12. Ronne-Engstro¨m E, Hillered L, Flink
R et al (1992) Intracerebral
microdialysis of extracellular amino
acids in the human epileptic focus.
J Cereb Blood Flow Metab
12:873–876. doi:
10.1038/jcbfm.1992.119
13. Hutchinson PJ, O’Connell MT, Nortje
J et al (2005) Cerebral microdialysis
methodology—evaluation of 20 kDa
and 100 kDa catheters. Physiol Meas
26:423–428. doi:
10.1088/0967-3334/26/4/008
14. Hillman J, A˚neman O, Anderson C
et al (2005) A Microdialysis technique
for routine measurement of
macromolecules in the injured human
brain. Neurosurgery 56:1264–1270.
doi:10.1227/01.NEU.0000159711.
93592.8D
15. Helmy A, Carpenter KLH, Skepper JN
et al (2009) Microdialysis of
cytokines: methodological
considerations, scanning electron
microscopy, and determination of
relative recovery. J Neurotrauma
26:549–561. doi:
10.1089/neu.2008.0719
16. Helmy A, Carpenter KLH, Menon DK
et al (2011) The cytokine response to
human traumatic brain injury:
temporal profiles and evidence for
cerebral parenchymal production.
J Cereb Blood Flow Metab
31:658–670. doi:
10.1038/jcbfm.2010.142
17. Chu J, Koudriavtsev V, Hjort K,
Dahlin AP (2014) Fluorescence
imaging of macromolecule transport in
high molecular weight cut-off
microdialysis. Anal Bioanal Chem
406:7601–7609. doi:
10.1007/s00216-014-8192-y
18. Dahlin AP, Wetterhall M, Caldwell
KD et al (2010) Methodological
aspects on microdialysis protein
sampling and quantification in
biological fluids: an in vitro study on
human ventricular CSF. Anal Chem
82:4376–4385. doi:
10.1021/ac1007706
19. Dahlin AP, Purins K, Clausen F et al
(2014) Refined microdialysis method
for protein biomarker sampling in
acute brain injury in the
neurointensive care setting. Anal
Chem 86:8671–8679. doi:
10.1021/ac501880u
20. Hillered L, Dahlin AP, Clausen F et al
(2014) Cerebral microdialysis for
protein biomarker monitoring in the
neurointensive care setting—a
technical approach. Front Neurol
5:245. doi:10.3389/fneur.2014.00245
21. Sakowitz OW, Santos E, Nagel A et al
(2013) Clusters of spreading
depolarizations are associated with
disturbed cerebral metabolism in
patients with aneurysmal subarachnoid
hemorrhage. Stroke 44:220–223. doi:
10.1161/STROKEAHA.112.672352
22. Feuerstein D, Manning A, Hashemi P
et al (2010) Dynamic metabolic
response to multiple spreading
depolarizations in patients with acute
brain injury: an online microdialysis
study. J Cereb Blood Flow Metab
30:1343–1355. doi:
10.1038/jcbfm.2010.17
23. Rogers ML, Feuerstein D, Leong CL
et al (2013) Continuous online
microdialysis using microfluidic
sensors: dynamic neurometabolic
changes during spreading
depolarization. ACS Chem Neurosci
4:799–807. doi:10.1021/cn400047x
24. Bhatia R, Hashemi P, Razzaq A et al
(2006) Application of rapid-sampling,
online microdialysis to the monitoring
of brain metabolism during aneurysm
surgery. Neurosurgery 58:ONS–
313–20. doi:10.1227/01.NEU.00002
08963.42378.83 (discussion ONS–
321)
25. Skoglund K, Hillered L, Purins K,
Tsitsopoulos PP (2014) The
neurological wake-up test does not
alter cerebral energy metabolism and
oxygenation in patients with severe
traumatic brain injury. Neurocrit Care.
doi:10.1007/s12028-013-9876-4
26. Adamides AA, Rosenfeldt FL, Winter
CD et al (2009) Brain tissue lactate
elevations predict episodes of
intracranial hypertension in patients
with traumatic brain injury. J Am Coll
Surg 209:531–539. doi:
10.1016/j.jamcollsurg.2009.05.028
27. Belli A, Sen J, Petzold A et al (2008)
Metabolic failure precedes intracranial
pressure rises in traumatic brain
injury: a microdialysis study. Acta
Neurochir (Wien) 150:461–470. doi:
10.1007/s00701-008-1580-3
28. Skjøth-Rasmussen J, Schulz M,
Kristensen SR, Bjerre P (2004)
Delayed neurological deficits detected
by an ischemic pattern in the
extracellular cerebral metabolites in
patients with aneurysmal subarachnoid
hemorrhage. J Neurosurg 100:8–15.
doi:10.3171/jns.2004.100.1.0008
29. Sarrafzadeh AS, Sakowitz OW,
Kiening KL et al (2002) Bedside
microdialysis: a tool to monitor
cerebral metabolism in subarachnoid
hemorrhage patients? Crit Care Med
30:1062–1070. doi:
10.1097/00003246-200205000-00018
30. Kett-White R, Hutchinson PJ, Al-
Rawi PG et al (2002) Cerebral oxygen
and microdialysis monitoring during
aneurysm surgery: effects of blood
pressure, cerebrospinal fluid drainage,
and temporary clipping on infarction.
J Neurosurg 96:1013–1019. doi:
10.3171/jns.2002.96.6.1013
31. Hlatky R, Valadka AB, Goodman JC
et al (2004) Patterns of energy
substrates during ischemia measured
in the brain by microdialysis.
J Neurotrauma 21:894–906. doi:
10.1089/0897715041526195
32. Tisdall MM, Smith M (2006) Cerebral
microdialysis: research technique or
clinical tool. Br J Anaesth 97:18–25.
doi:10.1093/bja/ael109
33. Enblad P, Valtysson J, Andersson J
et al (1996) Simultaneous intracerebral
microdialysis and positron emission
tomography in the detection of
ischemia in patients with subarachnoid
hemorrhage. J Cereb Blood Flow
Metab 16:637–644. doi:
10.1097/00004647-199607000-00014
34. Hutchinson PJ, Gupta AK, Fryer TF
et al (2002) Correlation between
cerebral blood flow, substrate delivery,
and metabolism in head injury: a
combined microdialysis and triple
oxygen positron emission tomography
study. J Cereb Blood Flow Metab
22:735–745. doi:
10.1097/00004647-200206000-00012
35. Hillered L, Valtysson J, Enblad P,
Persson L (1998) Interstitial glycerol
as a marker for membrane
phospholipid degradation in the
acutely injured human brain. J Neurol
Neurosurg Psychiatry 64:486–491
36. Clausen T, Alves OL, Reinert M et al
(2005) Association between elevated
brain tissue glycerol levels and poor
outcome following severe traumatic
brain injury. J Neurosurg
103:233–238. doi:
10.3171/jns.2005.103.2.0233
37. Schulz MK, Wang LP, Tange M,
Bjerre P (2000) Cerebral microdialysis
monitoring: determination of normal
and ischemic cerebral metabolisms in
patients with aneurysmal subarachnoid
hemorrhage. J Neurosurg 93:808–814.
doi:10.3171/jns.2000.93.5.0808
38. Agren-Wilsson A, Roslin M, Eklund A
et al (2003) Intracerebral microdialysis
and CSF hydrodynamics in idiopathic
adult hydrocephalus syndrome.
J Neurol Neurosurg Psychiatry
74:217–221
1525
39. Eide PK, Stanisic M (2010) Cerebral
microdialysis and intracranial pressure
monitoring in patients with idiopathic
normal-pressure hydrocephalus:
association with clinical response to
extended lumbar drainage and shunt
surgery. J Neurosurg 112:414–424.
doi:10.3171/2009.5.09122
40. Zauner A, Doppenberg EM,
Woodward JJ et al (1997) Continuous
monitoring of cerebral substrate
delivery and clearance: initial
experience in 24 patients with severe
acute brain injuries. Neurosurgery
41:1082–1091. doi:
10.1097/00006123-199711000-00011
(discussion 1091–1093)
41. Stuart RM, Schmidt M, Kurtz P et al
(2010) Intracranial multimodal
monitoring for acute brain injury: a
single institution review of current
practices. Neurocrit Care 12:188–198.
doi:10.1007/s12028-010-9330-9
42. Ibrahim MI, Abdullah M, Naing L
et al (2007) Cost effectiveness analysis
of using multiple neuromodalities in
treating severe traumatic brain injury
in a developing country like Malaysia.
Asian J Surg 30:261–266. doi:
10.1016/S1015-9584(08)60036-6
43. Patel HC, Menon DK, Tebbs S et al
(2002) Specialist neurocritical care
and outcome from head injury.
Intensive Care Med 28:547–553. doi:
10.1007/s00134-002-1235-4
44. Stein SC, Georgoff P, Meghan S et al
(2010) Relationship of aggressive
monitoring and treatment to improved
outcomes in severe traumatic brain
injury. J Neurosurg 112:1105–1112.
doi:10.3171/2009.8.JNS09738
45. Whitmore RG, Thawani JP, Grady MS
et al (2012) Is aggressive treatment of
traumatic brain injury cost-effective?
J Neurosurg 116:1106–1113. doi:
10.3171/2012.1.JNS11962
46. Elf K, Nilsson P, Enblad P (2002)
Outcome after traumatic brain injury
improved by an organized secondary
insult program and standardized
neurointensive care. Crit Care Med
30:2129
47. Sta˚hl N, Mellerga˚rd P, Hallstro¨m A
et al (2001) Intracerebral microdialysis
and bedside biochemical analysis in
patients with fatal traumatic brain
lesions. Acta Anaesthesiol Scand
45:977–985
48. Nordstro¨m C, Reinstrup P, Xu W et al
(2003) Assessment of the lower limit
for cerebral perfusion pressure in
severe head injuries by bedside
monitoring of regional energy
metabolism. Anesthesiology
98:809–814. doi:
10.1097/00000542-200304000-00004
49. Engstro¨m M, Polito A, Reinstrup P
et al (2005) Intracerebral microdialysis
in severe brain trauma: the importance
of catheter location. J Neurosurg
102:460–469. doi:
10.3171/jns.2005.102.3.0460
50. Timofeev I, Czosnyka M, Carpenter
KLH et al (2011) Interaction between
brain chemistry and physiology after
traumatic brain injury: impact of
autoregulation and microdialysis
catheter location. J Neurotrauma
28:849–860. doi:
10.1089/neu.2010.1656
51. Timofeev I, Carpenter KLH, Nortje J
et al (2011) Cerebral extracellular
chemistry and outcome following
traumatic brain injury: a microdialysis
study of 223 patients. Brain
134:484–494. doi:
10.1093/brain/awq353
52. Vespa PM, O Phelan K, McArthur D
et al (2007) Pericontusional brain
tissue exhibits persistent elevation of
lactate/pyruvate ratio independent of
cerebral perfusion pressure. Crit Care
Med 35:1153–1160. doi:10.1097/
01.CCM.0000259466.66310.4F
53. Stein NR, McArthur DL, Etchepare M,
Vespa PM (2012) Early cerebral
metabolic crisis after tbi influences
outcome despite adequate
hemodynamic resuscitation. Neurocrit
Care 17:49–57. doi:
10.1007/s12028-012-9708-y
54. Schmidt JM, Ko S-B, Helbok R et al
(2011) Cerebral perfusion pressure
thresholds for brain tissue hypoxia and
metabolic crisis after poor-grade
subarachnoid hemorrhage. Stroke
42:1351–1356. doi:
10.1161/STROKEAHA.110.596874
55. Vespa PM, McArthur D, O’Phelan K
et al (2003) Persistently low
extracellular glucose correlates with
poor outcome 6 months after human
traumatic brain injury despite a lack of
increased lactate: a microdialysis
study. J Cereb Blood Flow Metab
23:865–877. doi:
10.1097/
01.WCB.0000076701.45782.EF
56. Oddo M, Schmidt JM, Carrera E et al
(2008) Impact of tight glycemic
control on cerebral glucose
metabolism after severe brain injury: a
microdialysis study. Crit Care Med
36:3233–3238. doi:
10.1097/CCM.0b013e31818f4026
57. Dizdarevic K, Hamdan A,
Omerhodzic I, Kominlija-Smajic E
(2012) Modified Lund concept versus
cerebral perfusion pressure-targeted
therapy: a randomised controlled study
in patients with secondary brain
ischaemia. Clin Neurol Neurosurg
114:142–148. doi:
10.1016/j.clineuro.2011.10.005
58. Cesarini KG, Enblad P, Ronne-
Engstro¨m E et al (2002) early cerebral
hyperglycolysis after subarachnoid
haemorrhage correlates with
favourable outcome. Acta Neurochir
(Wien) 144:1121–1131. doi:
10.1007/s00701-002-1011-9
59. Schlenk F, Graetz D, Nagel A et al
(2008) Insulin-related decrease in
cerebral glucose despite
normoglycemia in aneurysmal
subarachnoid hemorrhage. Crit Care
12:R9. doi:10.1186/cc6776
60. Schmidt JM, Claassen J, Ko S-B et al
(2012) Nutritional support and brain
tissue glucose metabolism in poor-
grade SAH: a retrospective
observational study. Crit Care 16:R15.
doi:10.1186/cc11160
61. Vespa P, McArthur DL, Stein N et al
(2012) Tight glycemic control
increases metabolic distress in
traumatic brain injury: a randomized
controlled within-subjects trial. Crit
Care Med 40:1923–1929. doi:
10.1097/CCM.0b013e31824e0fcc
62. Vespa P, Boonyaputthikul R,
McArthur DL et al (2006) Intensive
insulin therapy reduces microdialysis
glucose values without altering
glucose utilization or improving the
lactate/pyruvate ratio after traumatic
brain injury. Crit Care Med
34:850–856. doi:
10.1097/01.CCM.0000201875.
12245.6F
63. Zetterling M, Hillered L, Enblad P
et al (2011) Relation between brain
interstitial and systemic glucose
concentrations after subarachnoid
hemorrhage. J Neurosurg 115:66–74.
doi:10.3171/2011.3.JNS10899
64. Magnoni S, Tedesco C, Carbonara M
et al (2012) Relationship between
systemic glucose and cerebral glucose
is preserved in patients with severe
traumatic brain injury, but glucose
delivery to the brain may become
limited when oxidative metabolism is
impaired: implications for glycemic
control. Crit Care Med 40:1785–1791.
doi:10.1097/CCM.0b013e318246bd45
65. Rostami E, Bellander BM (2011)
Monitoring of glucose in brain,
adipose tissue, and peripheral blood in
patients with traumatic brain injury: a
microdialysis study. J Diabetes Sci
Technol 5:596–604. doi:
10.1177/193229681100500314
66. Parkin M, Hopwood S, Jones DA et al
(2005) Dynamic changes in brain
glucose and lactate in pericontusional
areas of the human cerebral cortex,
monitored with rapid sampling on-line
microdialysis: relationship with
depolarisation-like events. J Cereb
Blood Flow Metab 25:402–413. doi:
10.1038/sj.jcbfm.9600051
1526
67. Sarrafzadeh A, Haux D, Ku¨chler I et al
(2004) Poor-grade aneurysmal
subarachnoid hemorrhage:
relationship of cerebral metabolism to
outcome. J Neurosurg 100:400–406.
doi:10.3171/jns.2004.100.3.0400
68. Paraforou T, Paterakis K, Fountas K
et al (2011) Cerebral perfusion
pressure, microdialysis biochemistry
and clinical outcome in patients with
traumatic brain injury. BMC Res
Notes 4:540. doi:
10.1186/1756-0500-4-540
69. Samuelsson C, Hillered L, Enblad P,
Ronne-Engstro¨m E (2009)
Microdialysis patterns in subarachnoid
hemorrhage patients with focus on
ischemic events and brain interstitial
glutamine levels. Acta Neurochir
(Wien) 151:437–446. doi:
10.1007/s00701-009-0265-x
70. Marcoux J, McArthur DA, Miller C
et al (2008) Persistent metabolic crisis
as measured by elevated cerebral
microdialysis lactate-pyruvate ratio
predicts chronic frontal lobe brain
atrophy after traumatic brain injury.
Crit Care Med 36:2871–2877. doi:
10.1097/CCM.0b013e318186a4a0
71. Vespa PM, Miller C, McArthur D et al
(2007) Nonconvulsive electrographic
seizures after traumatic brain injury
result in a delayed, prolonged increase
in intracranial pressure and metabolic
crisis. Crit Care Med 35:2830–2836.
doi:10.1097/01.CCM.0000295667.
66853.BC
72. Kett-White R, Hutchinson PJ, Al-
Rawi PG et al (2002) Adverse cerebral
events detected after subarachnoid
hemorrhage using brain oxygen and
microdialysis probes. Neurosurgery
50:1213–1221 (discussion
1221–1222)
73. Reinstrup P, Sta˚hl N, Mellerga˚rd P
et al (2000) Intracerebral microdialysis
in clinical practice: baseline values for
chemical markers during wakefulness,
anesthesia, and neurosurgery.
Neurosurgery 47:701–710. doi:
10.1227/00006123-200009000-00035
74. Nielsen TH, Olsen NV, Toft P,
Nordstro¨m C (2013) Cerebral energy
metabolism during mitochondrial
dysfunction induced by cyanide in
piglets. Acta Anaesthesiol Scand
57:793–801. doi:10.1111/aas.12092
75. Purins K, Enblad P, Wiklund L,
Lewe´n A (2012) Brain tissue
oxygenation and cerebral perfusion
pressure thresholds of ischemia in a
standardized pig brain death model.
Neurocrit Care 16:462–469. doi:
10.1007/s12028-012-9675-3
76. Vespa P, Prins M, Ronne-Engstro¨m E
et al (1998) Increase in extracellular
glutamate caused by reduced cerebral
perfusion pressure and seizures after
human traumatic brain injury: a
microdialysis study. J Neurosurg
89:971–982. doi:
10.3171/jns.1998.89.6.0971
77. Kinoshita K, Moriya T, Utagawa A
et al (2010) Change in brain glucose
after enteral nutrition in subarachnoid
hemorrhage. J Surg Res 162:221–224.
doi:10.1016/j.jss.2009.06.009
78. Chamoun R, Suki D, Gopinath SP et al
(2010) Role of extracellular glutamate
measured by cerebral microdialysis in
severe traumatic brain injury.
J Neurosurg 113:564–570. doi:
10.3171/2009.12.JNS09689
79. Oddo M, Levine JM, Frangos S et al
(2012) Brain lactate metabolism in
humans with subarachnoid
hemorrhage. Stroke 43:1418–1421.
doi:10.1161/STROKEAH
A.111.648568
80. Unterberg AW, Sakowitz OW,
Sarrafzadeh AS et al (2001) Role of
bedside microdialysis in the diagnosis
of cerebral vasospasm following
aneurysmal subarachnoid hemorrhage.
J Neurosurg 94:740–749. doi:
10.3171/jns.2001.94.5.0740
81. Nagel A, Graetz D, Schink T et al
(2009) Relevance of intracranial
hypertension for cerebral metabolism
in aneurysmal subarachnoid
hemorrhage. J Neurosurg 111:94–101.
doi:10.3171/2009.1.JNS08587
82. Nilsson OG, Brandt L, Ungerstedt U,
Sa¨veland H (1999) Bedside detection
of brain ischemia using intracerebral
microdialysis: subarachnoid
hemorrhage and delayed ischemic
deterioration. Neurosurgery
45:1176–1184 (discussion 1184–1185)
83. Schlenk F, Nagel A, Graetz D,
Sarrafzadeh AS (2008) Hyperglycemia
and cerebral glucose in aneurysmal
subarachnoid hemorrhage. Intensive
Care Med 34:1200–1207. doi:
10.1007/s00134-008-1044-5
84. Helbok R, Schmidt JM, Kurtz P et al
(2010) Systemic glucose and brain
energy metabolism after subarachnoid
hemorrhage. Neurocrit Care
12:317–323. doi:
10.1007/s12028-009-9327-4
85. Johnston AJ, Steiner LA, Coles JP
et al (2005) Effect of cerebral
perfusion pressure augmentation on
regional oxygenation and metabolism
after head injury. Crit Care Med
33:189–195. doi:10.1097/01.
CCM.0000149837.09225.BD
86. Johnston AJ, Steiner LA, Chatfield DA
et al (2004) Effect of cerebral
perfusion pressure augmentation with
dopamine and norepinephrine on
global and focal brain oxygenation
after traumatic brain injury. Intensive
Care Med 30:791–797. doi:
10.1007/s00134-003-2155-7
87. Chen HI, Stiefel MF, Oddo M et al
(2011) Detection of cerebral
compromise with multimodality
monitoring in patients with
subarachnoid hemorrhage.
Neurosurgery 69:53–63. doi:
10.1227/NEU.0b013e3182191451
(discussion 63)
88. Helbok R, Kurtz P, Schmidt MJ et al
(2012) Effects of the neurological
wake-up test on clinical examination,
intracranial pressure, brain metabolism
and brain tissue oxygenation in
severely brain-injured patients. Crit
Care 16:R226. doi:10.1186/cc11880
89. Oddo M, Milby A, Chen I et al (2009)
Hemoglobin concentration and
cerebral metabolism in patients with
aneurysmal subarachnoid hemorrhage.
Stroke 40:1275–1281. doi:
10.1161/STROKEAHA.108.527911
90. Soukup J, Zauner A, Doppenberg
EMR et al (2002) Relationship
between brain temperature, brain
chemistry and oxygen delivery after
severe human head injury: the effect
of mild hypothermia. Neurol Res
24:161–168. doi:
10.1179/016164102101199710
91. Oddo M, Frangos S, Milby A et al
(2009) Induced normothermia
attenuates cerebral metabolic distress
in patients with aneurysmal
subarachnoid hemorrhage and
refractory fever. Stroke 40:1913–1916.
doi:
10.1161/STROKEAHA.108.534115
92. Ho CL, Wang CM, Lee KK et al
(2008) Cerebral oxygenation, vascular
reactivity, and neurochemistry
following decompressive craniectomy
for severe traumatic brain injury.
J Neurosurg 108:943–949. doi:
10.3171/JNS/2008/108/5/0943
93. Nagel A, Graetz D, Vajkoczy P,
Sarrafzadeh AS (2009) Decompressive
craniectomy in aneurysmal
subarachnoid hemorrhage: relation to
cerebral perfusion pressure and
metabolism. Neurocrit Care
11:384–394. doi:
10.1007/s12028-009-9269-x
94. Gallagher CN, Carpenter KLH, Grice
P et al (2009) The human brain utilizes
lactate via the tricarboxylic acid cycle:
a 13C-labelled microdialysis and high-
resolution nuclear magnetic resonance
study. Brain 132:2839–2849. doi:
10.1093/brain/awp202
1527
95. Hillman J, Milos P, Yu ZQ et al (2006)
Intracerebral microdialysis in
neurosurgical intensive care patients
utilising catheters with different
molecular cut-off (20 and 100 kD).
Acta Neurochir (Wien) 148:319–324.
doi:10.1007/s00701-005-0670-8
96. Carpenter KLH, Jalloh I, Gallagher
CN et al (2014) (13)C-labelled
microdialysis studies of cerebral
metabolism in TBI patients. Eur J
Pharm Sci 57:87–97. doi:
10.1016/j.ejps.2013.12.012
97. Jalloh I, Carpenter KLH, Grice P et al
(2015) Glycolysis and the pentose
phosphate pathway after human
traumatic brain injury: microdialysis
studies using 1,2-(13)C2 glucose.
J Cereb Blood Flow Metab
35:111–120. doi:
10.1038/jcbfm.2014.177
98. Notkina N, Dahyot-Fizelier C, Gupta
AK (2012) In vivo microdialysis in
pharmacological studies of
antibacterial agents in the brain. Br J
Anaesth 109:155–160. doi:
10.1093/bja/aes216
99. Dahyot-Fizelier C, Timofeev I,
Marchand S et al (2010) Brain
microdialysis study of meropenem in
two patients with acute brain injury.
Antimicrob Agents Chemother
54:3502–3504. doi:
10.1128/AAC.01725-09
100. Charalambides C, Sgouros S, Sakas D
(2010) Intracerebral microdialysis in
children. Childs Nerv Syst
26:215–220. doi:
10.1007/s00381-009-1031-3
101. Richards DA, Tolias CM, Sgouros S,
Bowery NG (2003) Extracellular
glutamine to glutamate ratio may
predict outcome in the injured brain: a
clinical microdialysis study in
children. Pharmacol Res 48:101–109.
doi:10.1016/s1043-6618(03)00081-1
102. Tolias CM, Richards DA, Bowery NG,
Sgouros S (2002) Extracellular
glutamate in the brains of children
with severe head injuries: a pilot
microdialysis study. Childs Nerv Syst
18:368–374. doi:
10.1007/s00381-002-0623-y
103. McNay EC, Sherwin RS (2004) From
artificial cerebro-spinal fluid (aCSF) to
artificial extracellular fluid (aECF):
microdialysis perfusate composition
effects on in vivo brain ECF glucose
measurements. J Neurosci Methods
132:35–43. doi:
10.1016/j.jneumeth.2003.08.014
104. Marklund N, Blennow K, Zetterberg H
et al (2009) Monitoring of brain
interstitial total tau and beta amyloid
proteins by microdialysis in patients
with traumatic brain injury.
J Neurosurg 110:1227–1237. doi:
10.3171/2008.9.JNS08584
105. Clausen F, Marklund N, Lewe´n A et al
(2012) Interstitial F(2)-isoprostane
8-iso-PGF(2a) as a biomarker of
oxidative stress after severe human
traumatic brain injury. J Neurotrauma
29:766–775. doi:
10.1089/neu.2011.1754
106. Sen J, Smith M, Belli A et al (2005)
Extracellular fluid S100B in the
injured brain: a future surrogate
marker of acute brain injury? Acta
Neurochir (Wien) 147:897–900. doi:
10.1007/s00701-005-0526-2
107. Magnoni S, Esparza TJ, Conte V et al
(2012) Tau elevations in the brain
extracellular space correlate with
reduced amyloid-b levels and predict
adverse clinical outcomes after severe
traumatic brain injury. Brain
135:1268–1280. doi:
10.1093/brain/awr286
108. Helbok R, Schiefecker A, Delazer M
et al (2014) Cerebral tau is elevated
after aneurysmal subarachnoid
haemorrhage and associated with brain
metabolic distress and poor functional
and cognitive long-term outcome.
J Neurol Neurosurg Psychiatry. doi:
10.1136/jnnp-2013-307326
109. Antunes AP, Schiefecker AJ, Beer R
et al (2014) Higher brain extracellular
potassium is associated with brain
metabolic distress and poor outcome
after aneurysmal subarachnoid
hemorrhage. Crit Care 18:R119. doi:
10.1186/cc13916
110. Brody DL, Magnoni S, Schwetye KE
et al (2008) Amyloid-beta dynamics
correlate with neurological status in
the injured human brain. Science
321:1221–1224. doi:
10.1126/science.1161591
111. Petzold A, Tisdall MM, Girbes AR
et al (2011) In vivo monitoring of
neuronal loss in traumatic brain injury:
a microdialysis study. Brain
134:464–483. doi:
10.1093/brain/awq360
112. Parkin MC, Hopwood SE, Boutelle
MG, Strong AJ (2003) Resolving
dynamic changes in brain metabolism
using biosensors and on-line
microdialysis. Trends Anal Chem
22:487–497. doi:
10.1016/S0165-9936(03)00912-9
1528
